Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer.
Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer.
复制标题
DOI：
10.1097/jto.0b013e31820a0ec0
复制
发表时间：
2011-03
期刊：
影响因子：
--
通讯作者：
Ethier SP
中科院分区：
文献类型：
--
作者：
Cote ML;Haddad R;Edwards DJ;Atikukke G;Gadgeel S;Soubani AO;Lonardo F;Bepler G;Schwartz AG;Ethier SP
非小细胞肺癌的表皮生长因子受体（EGFR）突变预测对酪氨酸激酶抑制剂（TKIs）的反应。突变更常见于从不吸烟的人和东亚人，但关于非裔美国人肿瘤中EGFR突变的频率有相互矛盾的报道。在之前的病例对照肺癌研究中，我们选择了67名非裔美国人和77名高加索人的肿瘤来确定EGFR突变状态。突变分析使用Sequenom质阵分析仪（Sequenom, San Diego， CA）进行。总体而言，13.9%的研究人群携带EGFR突变。非裔美国人肿瘤中EGFR突变发生率为11.9%，白种人为15.6% （p=0.53）。在非裔美国人身上发现的所有突变都是外显子19的缺失。大多数突变发生在非吸烟的非裔美国人（7/8）和高加索人（8/12）中。这些结果表明，患有非小细胞肺癌（NSCLC）的非裔美国人携带体细胞EGFR突变的频率与患有NSCLC的高加索人相似。因此，临床医生不应将种族作为使用EGFR-TKIs的临床决策参数。
Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer predict response to tyrosine kinase inhibitors (TKIs). Mutations occur more commonly in never-smokers and East Asians but there are conflicting reports on the frequency of EGFR mutations in tumors from African Americans. Tumors from 67 African American and 77 Caucasian participants in previous case-control studies of lung cancer were selected to determine EGFR mutational status. Mutation analysis was performed using the Sequenom mass array analyzer (Sequenom, San Diego, CA). Overall, 13.9% of the study population carried an EGFR mutation. EGFR mutations occurred in 11.9% of tumors from African Americans compared with 15.6% in Caucasians (p=0.53). All mutations found in African Americans were deletions in exon 19. The majority of mutations were found in non-smokers among both African Americans (7/8) and Caucasians (8/12). These results indicate that African Americans with non-small cell lung cancer (NSCLC) harbor somatic EGFR mutations at a frequency similar to Caucasians with NSCLC. Thus, clinicians should not use race as a clinical decision parameter for the use of EGFR-TKIs.